Who
Carsten Brunn
President and CEO
Company insider
Files Form 4 as: President and CEO, Cartesian Therapeutics; Director, Surface Oncology.
In numbers
- Trades disclosed
- 90
- Buys
- 0
- Sells
- 22
- Bought
- $0
- Sold
- $999K
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 1 Dec 2018
- Last trade
- 6 Jan 2026
- Last filed
- 8 Jan 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 6 Jan 2026filed 8 Jan 2026 | RNAC Cartesian TherapeuticsBiotechnology | SEC FORM 4 Sold | $162K23,766 at $6.82 | filing |
| 6 Jan 2026filed 8 Jan 2026 | RNAC Cartesian TherapeuticsBiotechnology | SEC FORM 4 Sold | $162K23,766 at $6.82 | filing |
| 2 Jan 2026filed 6 Jan 2026 | RNAC Cartesian TherapeuticsBiotechnology | SEC FORM 4 Code A | —143,200 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | RNAC Cartesian Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —415,700 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | RNAC Cartesian Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —415,700 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | RNAC Cartesian TherapeuticsBiotechnology | SEC FORM 4 Code A | —143,200 at $0.00 | filing |
| 6 Jan 2025filed 7 Jan 2025 | RNAC Cartesian TherapeuticsBiotechnology | SEC FORM 4 Sold | $147K8,708 at $16.83 | filing |
| 3 Jan 2025filed 7 Jan 2025 | RNAC Cartesian TherapeuticsBiotechnology | SEC FORM 4 Sold | $143K8,563 at $16.72 | filing |
| 2 Jan 2025filed 6 Jan 2025 | RNAC Cartesian Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —169,100 at $0.00 | filing |
| 2 Jan 2025filed 6 Jan 2025 | RNAC Cartesian TherapeuticsBiotechnology | SEC FORM 4 Code A | —57,500 at $0.00 | filing |
| 2 Jan 2024filed 4 Jan 2024 | RNAC Cartesian Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,971,000 at $0.00 | filing |
| 2 Jan 2024filed 4 Jan 2024 | RNAC Cartesian TherapeuticsBiotechnology | SEC FORM 4 Code A | —4,654,100 at $0.00 | filing |
| 13 Nov 2023filed 15 Nov 2023 | RNAC Cartesian Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —1,000,000 | filing |
| 13 Nov 2023filed 15 Nov 2023 | RNAC Cartesian Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —330,000 | filing |
| 13 Nov 2023filed 15 Nov 2023 | RNAC Cartesian Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | $124K400,000 at $0.31 | filing |
| 13 Nov 2023filed 15 Nov 2023 | RNAC Cartesian Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —600,000 | filing |
| 13 Nov 2023filed 15 Nov 2023 | RNAC Cartesian Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —75,000 | filing |
| 13 Nov 2023filed 15 Nov 2023 | RNAC Cartesian Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —670,000 | filing |
| 13 Nov 2023filed 15 Nov 2023 | RNAC Cartesian Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —163,000 | filing |
| 13 Nov 2023filed 15 Nov 2023 | RNAC Cartesian Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —1,056,100 | filing |
News
No headline names them, or the companies they trade most, lately.